Svetlana Lucas

Svetlana Lucas, Ph.D., is a prominent biopharmaceutical executive and a recent addition to the Board of Directors at Jasper Therapeutics, effective June 18, 2024. She brings over 20 years of experience in strategy, commercialization, and business development, particularly in the fields of immunology and oncology.

Currently, she serves as the Chief Business Officer at Scribe Therapeutics, where she has established multiple strategic collaborations with major pharmaceutical companies, potentially worth over $4 billion. Prior to this role, she was the Senior Vice President of Business Development at Tizona Therapeutics, and she has held significant positions at Amgen, including Head of Oncology and Inflammation, where she was involved in key partnerships and investments in cancer immunotherapy.123

Dr. Lucas received her Ph.D. in Molecular Biology and Biochemistry from the California Institute of Technology and holds an undergraduate degree in Biology from Moscow State University. In addition to her role at Jasper, she serves on the board of aTyr Pharma, Inc. and acts as an advisor to Radar Therapeutics.124